Hematology/Oncology Division, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
J Surg Oncol. 2011 Mar 15;103(4):348-57. doi: 10.1002/jso.21696.
Neoadjuvant systemic breast cancer therapy is the administration of systemic therapy to eligible breast cancer patients prior to surgery. This treatment modality was developed out of necessity to downstage inoperable tumors, but it has evolved into a tool for breast conservation surgery. The neoadjuvant approach is also commonly used now to explore the efficacy of new therapeutics by assessing their impact on pathologic complete response or other endpoints. This article will review the foundations of this treatment modality and the latest progress in the field. Considering the heterogeneity of breast cancer, it is clear that no single treatment will fit all types of breast cancer. Thus, there is a need to understand the biological underpinnings of the different types of breast cancer in order to design better treatments that will ultimately improve the eradication rate of this disease.
新辅助全身乳腺癌治疗是指在手术前为符合条件的乳腺癌患者进行全身治疗。这种治疗方式的发展是出于使不可手术的肿瘤降级的需要，但它已经演变成一种用于保乳手术的工具。新辅助方法现在也常用于通过评估新疗法对病理完全缓解或其他终点的影响来探索其疗效。本文将回顾这种治疗方式的基础和该领域的最新进展。考虑到乳腺癌的异质性，显然没有一种单一的治疗方法适用于所有类型的乳腺癌。因此，需要了解不同类型乳腺癌的生物学基础，以便设计更好的治疗方法，最终提高这种疾病的清除率。
